Myasthenia Gravis Treatment Global Market Report 2024

Description

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the preceding timeframe can be credited to the adoption of cholinesterase inhibitors, advancements in thymectomy procedures, the implementation of immunosuppressive therapies, the introduction of plasma exchange, and heightened patient advocacy efforts.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the upcoming period is linked to factors such as the increased use of biologics and monoclonal antibodies, advancements in genetic and precision medicine, the rise of emerging immune modulators, and the implementation of neuroprotective strategies and biosimilar medications. Key trends expected during the forecast period encompass the adoption of digital therapeutics, collaborative research initiatives, patient-centric approaches, the utilization of real-world evidence, and the implementation of long-term safety monitoring.

The anticipated increase in the prevalence of myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis, characterized by autoimmune neuromuscular challenges leading to fatigue and weakness in skeletal muscles, necessitates comprehensive healthcare services for effective management. The surge in myasthenia gravis cases is contributing to heightened sales within the myasthenia gravis treatment market. For instance, data from the National Organization for Rare Disorders, a US-based non-profit supporting individuals with rare diseases, revealed an estimated prevalence of 14-40 cases per 100,000 individuals in the United States in January 2022. Similarly, a study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia in December 2021 estimated a global prevalence of 12.4 people per 100,000 for myasthenia gravis. Consequently, the increasing prevalence of myasthenia gravis is a significant driver of growth in the myasthenia gravis treatment market.

The growth of the myasthenia gravis treatment market is being propelled by the rise in healthcare spending. Healthcare spending, denoting the total financial resources allocated to the healthcare sector within a specific region, country, or organization, is crucial for addressing autoimmune neuromuscular disorders such as myasthenia gravis. This financial commitment ensures optimal patient care, effective symptom management, and an overall enhanced quality of life. For instance, according to the American Medical Association in March 2023, health spending in the United States witnessed a 2.7% increase in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upward trajectory in healthcare spending is a key factor driving the growth of the myasthenia gravis treatment market.

The myasthenia gravis treatment market is witnessing a prominent trend towards product innovations, with major companies actively engaged in the development of novel solutions to enhance their market standing. A case in point is Argenx SE, a Netherlands-based biopharmaceutical company, which secured approval from the U.S. Food and Drug Administration (FDA) in December 2021 for its groundbreaking drug, VYVGARTo (efgartigimod alfa-fcab). Specifically designed for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis, VYVGART stands out as the first and only FDA-approved neonatal Fc receptor (FcRn) blocker in the realm of generalized myasthenia gravis treatment. Argenx SE has further solidified its market position by entering into agreements in principle with various regional and national commercial payers, establishing value-based agreements to ensure patient access and cost predictability.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In December 2021, Merck, a Germany-based pharmaceutical company, executed the acquisition of Chord Therapeutics, a Switzerland-based pharmaceutical company, for an undisclosed amount. This strategic move empowered Merck by incorporating cladribine into its pipeline and acquiring rights to develop cladribine for generalized myasthenia gravis (gMG). Cladribine, known for its therapeutic impact on B and T cells, key contributors to autoimmune diseases such as generalized myasthenia gravis, expanded Merck's neuroinflammatory disease portfolio. This acquisition complemented Merck's existing neurology portfolio in multiple sclerosis (MS), reinforcing its presence in the neuroinflammatory disease domain.

Major companies operating in the myasthenia gravis treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics PLC, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Avadel Pharmaceuticals PLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., Zenyaku Kogyo Co. Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

North America was the largest region in the myasthenia gravis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myasthenia Gravis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myasthenia gravis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myasthenia gravis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myasthenia gravis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Treatment: Medication; Surgery; Other Treatments
2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
3) By End-Use: Hospitals; Clinics; Other End-Uses
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13759

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Myasthenia Gravis Treatment Market Size and Growth

5.1. Global Myasthenia Gravis Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Myasthenia Gravis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Myasthenia Gravis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myasthenia Gravis Treatment Market Segmentation

6.1. Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medication
Surgery
Other Treatments
6.2. Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
Other Medication Types
6.3. Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Other End-Uses

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

7.1. Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myasthenia Gravis Treatment Market

8.1. Asia-Pacific Myasthenia Gravis Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myasthenia Gravis Treatment Market

9.1. China Myasthenia Gravis Treatment Market Overview
9.2. China Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myasthenia Gravis Treatment Market

10.1. India Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myasthenia Gravis Treatment Market

11.1. Japan Myasthenia Gravis Treatment Market Overview
11.2. Japan Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myasthenia Gravis Treatment Market

12.1. Australia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myasthenia Gravis Treatment Market

13.1. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myasthenia Gravis Treatment Market

14.1. South Korea Myasthenia Gravis Treatment Market Overview
14.2. South Korea Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myasthenia Gravis Treatment Market

15.1. Western Europe Myasthenia Gravis Treatment Market Overview
15.2. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myasthenia Gravis Treatment Market

16.1. UK Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myasthenia Gravis Treatment Market

17.1. Germany Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myasthenia Gravis Treatment Market

18.1. France Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myasthenia Gravis Treatment Market

19.1. Italy Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myasthenia Gravis Treatment Market

20.1. Spain Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myasthenia Gravis Treatment Market

21.1. Eastern Europe Myasthenia Gravis Treatment Market Overview
21.2. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myasthenia Gravis Treatment Market

22.1. Russia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myasthenia Gravis Treatment Market

23.1. North America Myasthenia Gravis Treatment Market Overview
23.2. North America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myasthenia Gravis Treatment Market

24.1. USA Myasthenia Gravis Treatment Market Overview
24.2. USA Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myasthenia Gravis Treatment Market

25.1. Canada Myasthenia Gravis Treatment Market Overview
25.2. Canada Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myasthenia Gravis Treatment Market

26.1. South America Myasthenia Gravis Treatment Market Overview
26.2. South America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myasthenia Gravis Treatment Market

27.1. Brazil Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myasthenia Gravis Treatment Market

28.1. Middle East Myasthenia Gravis Treatment Market Overview
28.2. Middle East Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myasthenia Gravis Treatment Market

29.1. Africa Myasthenia Gravis Treatment Market Overview
29.2. Africa Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

30.1. Myasthenia Gravis Treatment Market Competitive Landscape
30.2. Myasthenia Gravis Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Baxter International Inc.
31.4. Biogen Idec
31.5. Astellas Pharma Inc.
31.6. CSL Limited
31.7. Chugai Pharmaceutical Co. Ltd.
31.8. Grifols S.A
31.9. UCB Inc.
31.10. Mitsubishi Tanabe Pharma Corp.
31.11. Genentech Inc.
31.12. Horizon Therapeutics plc
31.13. Amneal Pharmaceuticals Inc.
31.14. Zydus Lifesciences Limited
31.15. Kedrion SpA

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking

33. Global Myasthenia Gravis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market Future Outlook and Potential Analysis

35.1 Myasthenia Gravis Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Myasthenia Gravis Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Myasthenia Gravis Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer